Brief: Alpha Tau Announces First Patient Enrollment In Combination Trial Of Alpha Dart And Pembrolizumab
03/11/2021 17:15
Nov 3 (Reuters) - Alpha Tau HCCC.O :
* ALPHA TAU ANNOUNCES ENROLLMENT OF FIRST PATIENT IN
COMBINATION
TRIAL OF ALPHA DART AND PEMBROLIZUMAB
Source text for Eikon: urn:newsml:reuters.com:*:nPnJwP6Ca
Further company coverage: HCCC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer